Cost ‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
ConclusionsDapagliflozin was a very cost ‐effective treatment option for HFrEF patients in China according to the result of our model. Our findings will help doctors and health care payers to make decisions in clinical practice. Future real‐world studies of cost‐effectiveness of dapagliflozin based on Chinese population were also nee ded.
Source: ESC Heart Failure - Category: Cardiology Authors: Younan Yao,
Rongcheng Zhang,
Tao An,
Xinke Zhao,
Jian Zhang Tags: Original Research Article Source Type: research
More News: Cardiology | Cardiovascular | China Health | Dapagliflozin | Forxiga | Health Management | Heart | Heart Failure | Study